QIAGEN and Applied Biosystems Announce PCR Technologies License Agreement

06-Dec-2005

QIAGEN N.V. and Applied Biosystems Group, an Applera Corporation business, announced that they have entered into a license agreement. Under the terms of the agreement, Applied Biosystems has granted a license to QIAGEN under the expanded Applied Biosystems PCR (polymerase chain reaction) licensing program. The expanded program includes patents for real-time PCR and other important PCR-related technologies not licensed under the previous PCR licensing program. Financial terms of the license were not disclosed.

Although the foundational patents covering the PCR process expired in the United States in March 2005 and will expire elsewhere in March 2006, numerous other patents related to PCR remain in force. These surviving patents cover, for example, enzyme compositions, kits, and methods such as reverse transcription and DNA sequencing. Applied Biosystems will continue to offer licenses to these patents.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances